This report analyzes the venture capital (VC) investment activity in Q4 2024 in the Pharma sector.
The global pharma sector in Q4 2024 witnessed investments worth $6.3 billion, a decline of 0.1% compared to Q3 2024. In terms of investment volume, there was a rise of 6.2% to 171 VC investments in Q4 2024. Oncology was the top therapy area with 74 deals by 203 investors.
The global pharma sector in Q4 2024 witnessed investments worth $6.3 billion, a decline of 0.1% compared to Q3 2024. In terms of investment volume, there was a rise of 6.2% to 171 VC investments in Q4 2024. Oncology was the top therapy area with 74 deals by 203 investors.
Scope
- This report provides an overview of VC investment activity globally in Q4 2024 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q4 2024 in the Pharma sector.
Reasons to Buy
- Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma Venture Capital Activity in Q4 2024
3 Global VC Investment Trends in Pharma
4 Global Quarterly Funding Activity in Pharma
5 Notable Deals in Pharma
6 Global Mega Investments Trends in Pharma
7 Mega Investments Quarterly Funding Activity in Pharma
8 Global Investment Activity in Pharma by Deal Size
9 Global Investment Activity in Pharma by Deal Stages
10 Deal Activity in Pharma: Top Deal Stage Type Analysis
11 Pharma Regional Comparison - Q4 2024
12 Pharma Regional Investment Activity in Pharma by Value and Volume
13 Pharma Investment Review by Top 10 Countries
14 Top 10 Therapy Area Investment Review
15 Top Pharma Investors by Value in Q4 2024
16 Further Information
16.1 Methodology
17 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alentis Therapeutics
- Seaport Therapeutics
- Kailera Therapeutics
- Nuvig Therapeutics
- Metsera
- Alpha 9 Theranostics
- Triveni Bio
- Terray Therapeutics
- ADCendo
- Ottimo Pharma
- Maze Therapeutics
- City Therapeutics
- Trace Neuroscience
- AXONIS Therapeutics
- Angitia Biopharmaceuticals
- Evommune
- Metsera
